Drug induced lupus associated with Trastuzumab emtansine in a patient with metastatic breast cancer.
Oğuzhan YıldızAli Fuat GürbüzMelek Karakurt EryilmazMurat ArazTalat AykutÖzlem ŞahinNaciye Hilal BüyükboyacıZeliha ÇelikMustafa YıldırımPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)
Drug-induced lupus is a clinical syndrome that shares similar features with systemic lupus erythematosus (SLE). The majority of patients present with symptoms such as arthralgia and myalgia. Hydralazine and procainamide are high-risk drugs for drug-induced lupus. Symptoms usually develop after months or years of use, but may also develop suddenly. Our patient also received TDM-1 treatment for 18 months. We present a case of TDM-1-associated drug-induced lupus in a patient with metastatic breast cancer. This is the first case of TDM-1-related drug-induced lupus reported in the literature.
Keyphrases
- drug induced
- systemic lupus erythematosus
- metastatic breast cancer
- liver injury
- disease activity
- case report
- rheumatoid arthritis
- end stage renal disease
- ejection fraction
- systematic review
- chronic kidney disease
- prognostic factors
- combination therapy
- depressive symptoms
- physical activity
- sleep quality
- smoking cessation